{"id":"NCT00838435","sponsor":"BioMarin Pharmaceutical","briefTitle":"Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU","officialTitle":"A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2018-09-14","completion":"2018-09-14","firstPosted":"2009-02-06","resultsPosted":"2020-12-22","lastUpdate":"2020-12-22"},"enrollment":95,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Phenylketonuria"],"interventions":[{"type":"DRUG","name":"sapropterin dihydrochloride","otherNames":["Kuvan","Phenoptin","BH4","6R BH4"]}],"arms":[{"label":"sapropterin dihydrochloride","type":"EXPERIMENTAL"}],"summary":"This multicenter, open label study is designed to evaluate the safety of Kuvan® and its effect on neurocognitive function, blood Phe concentration, and growth in children with PKU who are 0-6 years old.","primaryOutcome":{"measure":"Full-Scale Intelligence Quotient (FSIQ) Score","timeFrame":"Assessments through 84 months.","effectByArm":[{"arm":"Kuvan 20 mg/kg Once Daily","deltaMin":101.06,"sd":14.039}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":19,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":95},"commonTop":["Pyrexia","Upper respiratory tract infection","Vomiting","Cough","Nasopharyngitis"]}}